-+ 0.00%
-+ 0.00%
-+ 0.00%

Anixa says Phase 1 breast cancer vaccine trial meets endpoints, Phase 2 preparations underway

PUBT·08/24/2026 12:55:53
Listen to the news
Anixa says Phase 1 breast cancer vaccine trial meets endpoints, Phase 2 preparations underway
  • Anixa Biosciences will present clinical updates at the Cantor Fitzgerald Global Healthcare Conference on Sept. 11, 2026.
  • Final Phase 1 breast cancer vaccine results were already presented, showing the study met its main goals, supporting Phase 2 planning.
  • Ovarian cancer CAR-T program lira-cel has moved to the highest dose cohort, adding lymphodepletion, with no dose-limiting toxicities reported.
  • Several treated patients have remained alive beyond one year, underpinning continued development in heavily pre-treated recurrent ovarian cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anixa Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA31702) on August 24, 2026, and is solely responsible for the information contained therein.